Jamali, A.Ram, N.Karim, S.Sattar, S.Rashid, M. S.Islam, N.2024-09-242024-09-242023-11Jamali A., Ram N., Karim S., Sattar S., Rashid M. S., Islam N.. Prescribing patterns of antidiabetic drugs and glycaemic control in type 2 diabetes patients visiting tertiary care hospital based in Karachi, Pakistan. International Journal of Community Medicine and Public Health. 2023 Nov; 10(11): 4082-40882394-60322394-6040https://imsear.searo.who.int/handle/123456789/227595Background: Diabetes mellitus (DM) is a global health concern with elevated blood glucose levels and insulin dysfunction. Our study analyzed antidiabetic drug prescriptions and their effectiveness in managing type 2 diabetes (T2DM) with or without comorbidities. We aimed to gain insights into prescribing practices and efficacy in diverse patient populations. Methods: This retrospective study was conducted at The Aga Khan University in Karachi, Pakistan, over a three-month period. It analysed prescriptions of anti-diabetic drugs for male and female patients aged 18 years and above with type 2 diabetes mellitus. Patient data, including prescribed drugs, diabetes duration, co-morbid conditions, and HbA1c levels, were reviewed using the hospital's Health Information Management System (HIMS). Results: Data from 552 diabetic patients were analysed. The mean age of participants with type-2 DM was 58 years, with 53.3% males and 46.7% females. 25.2% had diabetes for 5-10 years. Good glycaemic control was achieved by 48.7% of patients. Metformin (83.9%), dipeptidyl peptidase 4 inhibitors (DPP4) inhibitors (61.1%), and sodium-glucose transport 2 inhibitors (SGLT2) inhibitors (54.0%) were the most prescribed medications. Three-drug combinations were predominant (41.5%). Conclusions: Metformin was the most prescribed monotherapy for T2DM, followed by DPP4 inhibitors and SGLT2 inhibitors. Common combinations included DPP4 inhibitors with metformin, three-drug combinations with metformin, DPP4 inhibitors, and SGLT2 inhibitors, and four-drug combinations with metformin, DPP4 inhibitors, SGLT2 inhibitors, and sulfonylurea. DPP4 inhibitors were commonly used after metformin due to availability and cost-effectiveness. Glucagon-like peptide-1 inhibitors (GLP-1) analogs were less commonly prescribed due to cost, patient preference, and concerns about side effects.T2DMSGLT2GLP-1DPP4Journal ArticleIndiaDepartment of Medicine, Section of Endocrine, Aga Khan University Hospital, Karachi, PakistanDepartment of Medicine, Section of Endocrine, Aga Khan University Hospital, Karachi, PakistanDepartment of Medicine, Aga Khan University Hospital Karachi, PakistanDepartment of Medicine, Aga Khan University Hospital Karachi, PakistanDepartment of Medicine, Section of Endocrine, Aga Khan University Hospital, Karachi, PakistanDepartment of Medicine, Section of Endocrine, Aga Khan University Hospital, Karachi, Pakistan